Let's discuss whether Intuitive Surgical stock is a buy now. For more than two decades, the da Vinci surgical system has represented the industry standard for minimally invasive robotic-assisted ...

INTUITIVE SURGICAL, INC. (ISRG) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 75% based on the firm’s underlying fundamentals and ...

The company’s stock is surging, having grown around 60% over the past 12 months. Its Q4 2024 results showed considerable growth, with Da Vinci procedures increasing by 18%. Intuitive Surgical ...

Leerink Partners’ price target would indicate a potential downside of 4.55% from the stock’s current price. A number of other equities research analysts also recently weighed in on ISRG.

The business model, with 84% recurring revenue from instruments, accessories, and services, ensures stable growth and high margins, despite occasional stock volatility. Financially, ISRG boasts ...

Intuitive Surgical (NASDAQ: ISRG) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $2.4 billion and adjusted earnings of ...

JPMorgan Chase & Co. currently has an overweight rating on the medical equipment provider’s stock. ISRG has been the topic of a number of other research reports. Leerink Partners raised their ...

Intuitive Surgical ISRG reported fourth-quarter 2024 adjusted earnings per share (EPS) of $2.21, which beat the Zacks Consensus Estimate of $1.65 by 24.9%. The bottom line improved 38.1% year over ...

Intuitive Surgical ISRG reported fourth-quarter 2024 adjusted earnings per share (EPS) of $2.21, which beat the Zacks Consensus Estimate of $1.65 by 24.9%. The bottom line improved 38.1% year over ...

Oppenheimer expressed a cautious outlook on the stock. The analyst firm outlined several concerns impacting their stance: the U.S. market for Intuitive Surgical's products appears to be nearing ...